GB201621737D0 - Compositions and methods of treatment - Google Patents
Compositions and methods of treatmentInfo
- Publication number
- GB201621737D0 GB201621737D0 GBGB1621737.4A GB201621737A GB201621737D0 GB 201621737 D0 GB201621737 D0 GB 201621737D0 GB 201621737 A GB201621737 A GB 201621737A GB 201621737 D0 GB201621737 D0 GB 201621737D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- compositions
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1621737.4A GB201621737D0 (en) | 2016-12-20 | 2016-12-20 | Compositions and methods of treatment |
PCT/GB2017/053847 WO2018115877A2 (en) | 2016-12-20 | 2017-12-20 | Compositions and methods of treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1621737.4A GB201621737D0 (en) | 2016-12-20 | 2016-12-20 | Compositions and methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201621737D0 true GB201621737D0 (en) | 2017-02-01 |
Family
ID=58284277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1621737.4A Ceased GB201621737D0 (en) | 2016-12-20 | 2016-12-20 | Compositions and methods of treatment |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201621737D0 (en) |
WO (1) | WO2018115877A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111387133B (en) * | 2020-02-25 | 2021-04-16 | 中国农业大学 | Method for establishing model for inhibiting mouse mastitis by using Klebsiella pneumoniae bacteriophage |
IT202100007211A1 (en) * | 2021-03-24 | 2022-09-24 | Softmining S R L | PEPTIDE WITH ANTIMICROBIAL ACTIVITY |
IT202100007214A1 (en) * | 2021-03-24 | 2022-09-24 | Softmining S R L | PEPTIDE WITH ANTIMICROBIAL ACTIVITY |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
-
2016
- 2016-12-20 GB GBGB1621737.4A patent/GB201621737D0/en not_active Ceased
-
2017
- 2017-12-20 WO PCT/GB2017/053847 patent/WO2018115877A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2018115877A2 (en) | 2018-06-28 |
WO2018115877A3 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2582482B (en) | CASZ compositions and methods of use | |
HK1258205A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
IL258955A (en) | Compositions and methods for treatment of cancer | |
GB2582100B (en) | CAS12C Compositions and methods of use | |
HK1248531A1 (en) | Immunomodulatory compositions and methods of use thereof | |
ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
ZA201906169B (en) | Synthekine compositions and methods of use | |
HK1247789A1 (en) | Compositions and methods for treatment of edema | |
HK1249515A1 (en) | Methods and compositions for the prevention and treatment of hearing loss | |
ZA201902781B (en) | Compositions and methods for the treatment of xerostomia | |
HK1255221A1 (en) | Methods of treatment using cadotril compositions | |
HK1258502A1 (en) | Compositions and methods for treatment of homocystinuria | |
ZA201808232B (en) | Compositions and methods for the treatment of cancer | |
HK1252057A1 (en) | Novel method of use and compositions | |
HK1250345A1 (en) | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same | |
IL259710A (en) | Compositions and methods of treatment for mvid and related diseases | |
HK1245101A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
ZA201900984B (en) | Methods and compositions for the treatment of warts | |
HK1255695A1 (en) | Composition and methods for the treatment of blepharoptosis | |
GB201511799D0 (en) | Composition and methods of treatment | |
GB2591422B (en) | Maca compositions and methods of use | |
GB201621737D0 (en) | Compositions and methods of treatment | |
HK1248527A1 (en) | Dental compositions and methods of use | |
GB201605127D0 (en) | Composition and methods of treatment | |
DK3313207T3 (en) | Compositions and methods for the treatment of malnutrition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |